Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
C1 Inhibitor, Human recombinant protein
Plasma protease C1, inhibitor, C1inh, C1 Esterase Protein, C1-inhibiting factor, Serpin G1
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P05155 |
|---|---|
| Calculated MW | 49.4 kDa |
| Gene ID | 710 |
|---|---|
| Gene Symbol | SERPING1 |
| Other Names | Plasma protease C1, inhibitor, C1inh, C1 Esterase Protein, C1-inhibiting factor, Serpin G1 |
| Gene Source | Human |
| Source | CHO cells |
| Assay&Purity | SDS-PAGE; ≥95% |
| Assay2&Purity2 | HPLC; |
| Recombinant | Yes |
| Sequence | VEPILEVSSL PTTNSTTNSA TKITANTTDE PTTQPTTEPT TQPTIQPTQP TTQLPTDSPT QPTTGSFCPG PVTLCSDLES HSTEAVLGDA LVDFSLKLYH AFSAMKKVET NMAFSPFSIA SLLTQVLLGA GENTKTNLES ILSYPKDFTC VHQALKGFTT KGVTSVSQIF HSPDLAIRDT FVNASRTLYS SSPRVLSNNS DANLELINTW VAKNTNNKIS RLLDSLPSDT RLVLLNAIYL SAKWKTTFDP KKTRMEPFHF KNSVIKVPMM NSKKYPVAHF IDQTLKAKVG QLQLSHNLSL VILVPQNLKH RLEDMEQALS PSVFKAIMEK LEMSKFQPTL LTLPRIKVTT SQDMLSIMEK LEFFDFSYDL NLCGLTEDPD LQVSAMQHQT VLELTETGVE AAAASAISVA RTLLVFEVQQ PFLFVLWDQQ HKFPVFMGRV YDPRA |
| Target/Specificity | C1 inhibitor |
| Application Notes | Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C. |
| Format | Lyophilized powder |
| Storage | -20°C; Sterile filtered through a 0.2 micron filter. Lyophilized with 10 mM sodium phosphate, pH 7.5. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
C1 Inhibitor is a member of the serpin family of structurally related proteins, and is the primary regulator of the immune complement system. C1 Inhibitor is a protease inhibitor that functions to inhibit the complement system in order to prevent over-activation or spontaneous activation. Inhibition is achieved by binding to and irreversibly inhibiting the C1r and C1s proteases of the C1 complex, which has the effect of shutting down all subsequent downstream events in the complement activation cascade. C1inhibitor can also inhibit various other proteases, including Kallikrein, Factor XIa, and Factor XIIa. Deficiencies in C1inhibitor are the primary cause of hereditary angioedema (HAE, hereditary angioneurotic edema), a disease characterized by edema in the respiratory and gastrointestinal tracts. In certain clinical situations, the direct administration of C1inhibitor can be used to treat HAE and certain other conditions. Recombinant Human C1 Inhibitor is a highly glycosylated glycoprotein containing 445 amino acid residues (49.4kDa), corresponding to amino acids 56 – 500 of the C1 inhibitor precursor, and is fully functional in its ability to inhibit the C1 complex. Glycosylated C1 Inhibitor migrates at an apparent molecular weight of approximately 80-90 kDa by SDS PAGE analysis under reducing conditions.
References
Que B.G.,et al.Biochem. Biophys. Res. Commun. 137:620-625(1986).
Bock S.C.,et al.Biochemistry 25:4292-4301(1986).
Carter P.E.,et al.Eur. J. Biochem. 173:163-169(1988).
Carter P.E.,et al.Eur. J. Biochem. 197:301-308(1991).
Heus J.,et al.Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
